couter

ACHVAchieve Life Sciences, Inc.

Achieve Life Sciences, Inc. (ACHV) is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. The company’s next catalyst is Nov 10, 2026 — Q4 2026 Earnings Release, which will test whether the business can deliver strong top-line growth and guidance, with a focus on new product launches and margin expansion.

  • ACHV has reported $0 revenue and a net loss of $109.55M for the period ending 2026-06-30.
  • Free cash flow (TTM) is -$76.35M, and shareholders’ equity stands at $21.52M.
  • The company has secured $354 million in financing to address cash runway concerns, though the stock fell 21.7% after the update .

The Read

Despite securing $354 million in financing to address cash runway concerns, ACHV's stock fell 21%.
Nov 10, 2026 — Q4 2026 Earnings Release
Chart by TradingView

The schedule

  • Tue10Nov

    This release will test the company's ability to maintain momentum from Q3, with a focus on revenue growth and cost management. The last earnings print showed a bearish trend, but the path band suggests a potential rebound.

  • Tue11May

    The Q1 2027 earnings release will test the company's ability to deliver on its long-term growth strategy, particularly in terms of product launches and market expansion. The last earnings print showed a bearish trend, but the path band suggests a potential rebound.

  • Tue10Aug

    This release will test the company's ability to maintain its growth trajectory, with a focus on revenue growth and cost efficiency. The last earnings print showed a bearish trend, but the path band suggests a potential rebound.

  • Tue9Nov
  • Tue8Feb

Past

  • Tue11Aug

    Actual outcome: Bull · $8.50 at outcome

    ACHV beat estimates with EPS of -1.64, matching expectations, but the stock surged 25.3% post-earnings due to Morgan Stanley's Overweight initiation and positive sentiment around the anti-smoking agent. The rally was driven by strategic momentum and institutional interest, moving past the bull target of $7.85.

    The earnings release will test the company's ability to deliver consistent revenue and margin improvements, following a recent cash runway update that highlighted liquidity concerns. This differs from the last print where guidance cuts overshadowed revenue growth.

  • Tue12May

    Actual outcome: Bear · $4.69 at outcome

    Although Achieve Life Sciences reported in-line Q1 EPS and secured a massive $354 million financing package to resolve its cash runway concerns, the stock fell 21.7% following the update. The sharp sell-off was driven by the disclosure of FDA inspection issues at a third-party manufacturer, which is expected to trigger a Complete Response Letter (CRL) and delay the cytisinicline NDA resubmission to Q4 2026.

    ACHV's Q1 print comes with the stock at $5.99 and extremely overbought (RSI 77.6). Management must address the $28M cash position against an accelerating pre-commercial burn.